New data from the POETYK PsA-Phase III trial, presented at the 2025 EULAR Congress, demonstrate that Bristol Myers Squibb’s Sotyktu (deucravacitinib) significantly improves joint and skin symptoms in ...

This gives us both state-of-the-art diagnostic capabilities for prostate cancer and gives us state-of-the art treatments for prostate cancers that have spread,” says radiation oncologist Dr. Abraham ...